170 related articles for article (PubMed ID: 27181838)
1. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Lee SY; Jung DK; Choi JE; Jin CC; Hong MJ; Do SK; Kang HG; Lee WK; Seok Y; Lee EB; Jeong JY; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Sci Rep; 2016 May; 6():25952. PubMed ID: 27181838
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
[TBL] [Abstract][Full Text] [Related]
3. Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer.
Lee SY; Jung DK; Choi JE; Jin CC; Hong MJ; Do SK; Kang HG; Lee WK; Seok Y; Lee EB; Jeong JY; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Gene; 2017 Jan; 599():28-35. PubMed ID: 27838455
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.
Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Yoshida H; Yagi Y; Sakamori Y; Nagai H; Hirai T; Kim YH
Sci Rep; 2017 Mar; 7():45124. PubMed ID: 28332580
[TBL] [Abstract][Full Text] [Related]
5. A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
Hong MJ; Lee SY; Choi JE; Jin CC; Kang HJ; Baek SA; Lee SY; Shin KM; Jeong JY; Lee WK; Yoo SS; Lee J; Cha SI; Kim CH; Son JW; Park JY
Oncotarget; 2016 Mar; 7(13):15948-58. PubMed ID: 26893365
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in Non-Small Cell Lung Cancer.
Choi SH; Jin CC; Do SK; Lee SY; Choi JE; Kang HG; Kim JH; Lee JH; Hong MJ; Lee WK; Jeong JY; Shin KM; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Oncology; 2020; 98(7):468-477. PubMed ID: 32252059
[TBL] [Abstract][Full Text] [Related]
7. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Minari R; Bonatti F; Mazzaschi G; Dodi A; Facchinetti F; Gelsomino F; Cinquegrani G; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Quaini F; Ardizzoni A; Tiseo M
Tumori; 2022 Feb; 108(1):47-55. PubMed ID: 34002648
[TBL] [Abstract][Full Text] [Related]
11. An expression quantitative trait locus variant for LKB1 gene predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer.
Seo H; Jung DK; Kang HG; Jeong JY; Lee SY; Choi JE; Hong MJ; Do SK; Lee JH; Lee WK; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Cancer Genet; 2018 Dec; 228-229():73-82. PubMed ID: 30553476
[TBL] [Abstract][Full Text] [Related]
12. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
Planchard D; Yokoi T; McCleod MJ; Fischer JR; Kim YC; Ballas M; Shi K; Soria JC
Clin Lung Cancer; 2016 May; 17(3):232-236.e1. PubMed ID: 27265743
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.
Park HS; Lim SM; Shin HJ; Cho A; Shin JG; Lee MG; Kim HR; Kim JH; Cho BC
Pharmacogenet Genomics; 2016 Mar; 26(3):116-25. PubMed ID: 26641474
[TBL] [Abstract][Full Text] [Related]
14. Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer.
Zhao Y; Wang Z; Shi X; Liu T; Yu W; Ren X; Zhao H
Technol Cancer Res Treat; 2023; 22():15330338231202307. PubMed ID: 37728201
[No Abstract] [Full Text] [Related]
15. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
Xu X; Huang Z; Zheng L; Fan Y
Int J Cancer; 2018 Jun; 142(11):2344-2354. PubMed ID: 29318609
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
Powrózek T; Mlak R; Krawczyk P; Bartoń S; Biernacka B; Małecka-Massalska T; Milanowski J
Clin Transl Oncol; 2016 Jan; 18(1):33-9. PubMed ID: 26148901
[TBL] [Abstract][Full Text] [Related]
17. Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies.
Nishii K; Hotta K; Ninomiya K; Kato Y; Ichihara E; Ohashi K; Ninomiya T; Kubo T; Rai K; Tabata M; Maeda Y; Kiura K
Respir Investig; 2019 Sep; 57(5):460-465. PubMed ID: 31186170
[TBL] [Abstract][Full Text] [Related]
18. Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics.
Liu HF; Liu JS; Deng JH; Wu RR
Genet Mol Res; 2016 Dec; 15(4):. PubMed ID: 28081275
[TBL] [Abstract][Full Text] [Related]
19. HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer.
Jiang T; Jin Q; Wang J; Wu F; Chen J; Chen G; Huang Y; Chen J; Cheng Y; Wang Q; Pan Y; Zhou J; Shi J; Xu X; Lin L; Zhang W; Zhang Y; Liu Y; Fang Y; Feng J; Wang Z; Hu S; Fang J; Shu Y; Cui J; Hu Y; Yao W; Li X; Lin X; Wang R; Wang Y; Shi W; Feng G; Ni J; Mao B; Ren D; Sun H; Zhang H; Chen L; Zhou C; Ren S
Clin Cancer Res; 2023 Dec; 29(23):4830-4843. PubMed ID: 37449971
[TBL] [Abstract][Full Text] [Related]
20. [Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer].
Jiang Z; Pan Z; Ren X
Zhongguo Fei Ai Za Zhi; 2017 Feb; 20(2):138-142. PubMed ID: 28228226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]